Profil Adenokarsinoma Kolon di RSUP Prof Dr. R. D. Kandou dan Siloam Hospitals Periode Januari – Juni Pemberian Kombinasi 5FU-Leucovorin dengan Phaleria macrocarpa terhadap Proliferasi Sel dan Diameter Adenokarsinoma Kolon Tikus Sprague dawley. PROPOLIS TERHADAP KSPRESI PROTEIN CASPASE 8, APOPTOSIS, DAN PROLIFERASI PADA KULTUR SEL ADENOKARSINOMA KOLON (WiDr).

Author: Zolonris Gazahn
Country: Ethiopia
Language: English (Spanish)
Genre: Software
Published (Last): 16 October 2006
Pages: 347
PDF File Size: 16.13 Mb
ePub File Size: 8.91 Mb
ISBN: 562-7-18901-609-6
Downloads: 85163
Price: Free* [*Free Regsitration Required]
Uploader: Yomi

Pengamatan ekspresi protein Caspase 8 dilakukan dengan metode imunositokimia, pengamatan apoptosis dilakukan dengan double adenokarsnioma menggunakan pewarnaan akridin oranye—etidium bromide, sedangkan pengamatan proliferasi menggunakan MTT assay dengan doubling time.

Also indicated for previously untreated advanced colorectal cancer in combination with 5-FU and leucovorin. Characteristic toxicity occurred in the FU schedules and thrombocytopenia and hand-foot syndrome were more prominent in the CAP regimens. Pembedahan tetap merupakan pilihan utama dengan modalitas lainnya berupa kemoterapi, radiasi dan imunoterapi seperti P.

It is also indicated for second-line treatment in patients who have progressed on a first-line bevacizumab-containing regimen.

Cancer Statistics Working Group. Current standard therapy for colon cancer involves combination chemotherapy.

Perpustakaan Unika Atma Jaya

No head-to-head comparisons between panitumumab containing combinations versus cetuximab or even bevacizumab anti-VEGFR monoclonal antibody chemotherapy combinations in patients with wild-type KRAS tumors have been reported, leaving it up to the oncologist to prioritize the choice or sequence of monoclonals in this patient population.

Capecitabine itself is inactive. Introduction The incidence of colon cancer in the world is still high and the most cause of death of non-communicable disease category.


Surat Data Diri Penulis. Masters thesis, Master of Biomedical Science. Adjuvant Chemotherapy for Colorectal Cancer. Ongoing adjuvant trials are investigating additional risk stratification of stage II colon cancer based on clinicopathological and molecular markers ECOG trial.

Wang X dan Zhang Y. Binds lolon and stabilizes ternary complex of FdUTP intracellular active metabolite of adenokarzinoma and thymidylate synthetase Adenokarsinmoaaugmenting cytotoxic effects of 5-fluorouracil. Inactive in its parent form.


This page is licensed under a Creative Commons Attribution License. Indicated in combination with 5-fluorouracil, leucovorin, irinotecan FOLFIRI for metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin regimen. View full drug information Capecitabine Xeloda Fluoropyrimidine carbamate prodrug from of 5-fluorouracil 5-FU. American Journal of Clinical Oncology.

Journal of Agricultural and Food Chemistry, 52 Aenokarsinoma study used a female Sprague dawley white rats were divided into 4 groups: Statistically significant benefit in overall survival and progression- free adenokarsijoma was observed for regorafenib over placebo in patients with mCRC in whom all approved standard therapies have failed.

Targeting Apoptosis Pathways in Cancer Therapy. Cycles were repeated every 2 weeks. Penelitian dilakukan pada kultur sel WiDr dengan perlakuan pemberian dosis ekstrak ethanol propolis, kontrol positif adenokarsiomakombinasi ekstrak ethanol propolis dengan 5-FU, dan kontrol negatif tanpa obat.

Journal of Surgery [Jurnalul de Chirurgie]. They concluded that the overall response rate for cetuximab plus FOLFOX-4 was higher than with FOLFOX-4 alone though a statistically significant increase in odds for a response with the adenokrasinoma of cetuximab could not be established, except in patients with KRAS wild-type tumors, for whom the addition of cetuximab increased chance of response and lowered risk of disease progression.


Jurnal e-CliniC (eCl)

Click here to sign up. In another observational study from the same cohort of patients, patients were prospectively monitored and physical adenokarainoma was recorded. Regorafenib Stivargaa kinase inhibitor, was approved in September Sebagian besar pasien kanker kolorektal didiagnosis dalam stadium yang sudah tidak dapat dioperasi.

The addition of anti-EGFR antibody treatment to standard chemotherapy regimens for patients with advanced colorectal cancer improves progression-free survival for those with wild-type but not mutant KRAS status. The results of both studies suggest clinical benefit of adding panitumumab to chemotherapy for patients with wild-type KRAS colorectal cancer, in adenkarsinoma of improving progression-free survival PFS and response rate.

Colorectal Cancer, Diagnosis, and Clinical Management.

Complementary and Alternative Medicine in the United States. Jurnal Kedokteran Media Medika Indonesiana. Remember me on this computer. Journal Medicine Food, aeenokarsinoma 6: Fulda S, Debatin KM. Keywords Adenokarsinoma kolon; P. Redox Reactivity in Propolis: A Medicine the Legacy of the Gods. This information is to be derived from information on tumor biology, patient performance status, organ function, and pharmacogenomics testing. ABC of colorectal cancer, 2nd ed.

New Jersey, Wiley Blackwell.

Cetuximab-bound EGF receptor inhibits activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased production of matrix metalloproteinase and vascular endothelial growth factor. Life Sci, 68 8: Skip to main content.

Tumor kolon diperoleh dengan induksi 1,2-DMH subkutan.